Anixa Biosciences (ANIX) 10-Q 6 Sep 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jul. 31, 2023	Sep. 06, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--10-31
Entity File Number	001-37492
Entity Registrant Name	ANIXA BIOSCIENCES, INC.
Entity Central Index Key	0000715446
Entity Tax Identification Number	11-2622630
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3150 Almaden Expressway
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95118
City Area Code	(408)
Local Phone Number	708-9808
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	ANIX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,070,022

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jul. 31, 2023	Oct. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,198	$ 12,360
Short-term investments	22,336	17,327
Receivables	334	47
Prepaid expenses and other current assets	532	466
Total current assets	26,400	30,200
Operating lease right-of-use asset	178	212
Total assets	26,578	30,412
Current liabilities:
Accounts payable	94	265
Accrued expenses	1,712	1,726
Operating lease liability	51	46
Total current liabilities	1,857	2,037
Operating lease liability, non-current	136	175
Total liabilities	1,993	2,212
Commitments and contingencies (Note 10)
Shareholders’ equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,017,770 and 30,913,902 shares issued and outstanding as of July 31, 2023 and October 31, 2022, respectively	310	309
Additional paid-in capital	250,716	247,123
Accumulated deficit	(225,506)	(218,385)
Total shareholders’ equity	25,520	29,047
Noncontrolling interest (Note 2)	(935)	(847)
Total equity	24,585	28,200
Total liabilities and equity	26,578	30,412
Series A Convertible Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jul. 31, 2023	Oct. 31, 2022
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	31,017,770	30,913,902
Common stock, shares outstanding	31,017,770	30,913,902
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Income Statement [Abstract]
Revenue			$ 210
Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses			161
Research and development expenses (including non-cash share-based compensation expenses of $520, $771, $1,517 and $3,014, respectively)	1,088	1,445	3,154	5,018
General and administrative expenses (including non-cash share-based compensation expenses of $697, $675, $1,990 and $2,531, respectively)	1,756	1,352	4,855	5,248
Total operating costs and expenses	2,844	2,797	8,170	10,266
Loss from operations	(2,844)	(2,797)	(7,960)	(10,266)
Interest income	296	22	751	24
Net loss	(2,548)	(2,775)	(7,209)	(10,242)
Less: Net loss attributable to noncontrolling interest	(37)	(29)	(88)	(123)
Net loss attributable to common shareholders	$ (2,511)	$ (2,746)	$ (7,121)	$ (10,119)
Net loss per common share attributable to common shareholders:
Basic	$ (0.08)	$ (0.09)	$ (0.23)	$ (0.33)
Diluted	$ (0.08)	$ (0.09)	$ (0.23)	$ (0.33)
Weighted average common shares outstanding:
Basic	30,974	30,451	30,941	30,244
Diluted	30,974	30,451	30,941	30,244

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Research and Development Expense [Member]
Stock-based payment arrangement, expense	$ 520	$ 771	$ 1,517	$ 3,014
General and Administrative Expense [Member]
Stock-based payment arrangement, expense	$ 697	$ 675	$ 1,990	$ 2,531

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Shareholders Equity [Member]	Noncontrolling Interest [Member]
Balance at Oct. 31, 2021	$ 34,767	$ 301	$ 239,927	$ (204,790)	$ 35,438	$ (671)
Balance, shares at Oct. 31, 2021		30,050,894
Stock option compensation to employees and directors	4,928		4,928		4,928
Common stock issued upon exercise of stock options and warrants	830	$ 6	824		830
Common stock issued upon exercise of stock options and warrants, shares		577,473
Common stock issued to consultants	72		72		72
Common stock issued to consultants, shares		22,662
Net loss	(10,242)			(10,119)	(10,119)	(123)
Balance at Jul. 31, 2022	30,907	$ 307	246,303	(214,909)	31,701	(794)
Balance, shares at Jul. 31, 2022		30,653,418
Stock options and warrants issued to consultants	546		546		546
Common stock issued pursuant to employee stock purchase plan	6		6		6
Common stock issued pursuant to employee stock purchase plan, shares		2,389
Balance at Apr. 30, 2022	31,406	$ 302	244,032	(212,163)	32,171	(765)
Balance, shares at Apr. 30, 2022		30,154,708
Stock option compensation to employees and directors	1,329		1,329		1,329
Stock options issued to consultants	109		109		109
Common stock issued upon exercise of stock options and warrants	830	$ 5	825		830
Common stock issued upon exercise of stock options and warrants, shares		496,048
Common stock issued to consultants	8		8		8
Common stock issued to consultants, shares		2,662
Net loss	(2,775)			(2,746)	(2,746)	(29)
Balance at Jul. 31, 2022	30,907	$ 307	246,303	(214,909)	31,701	(794)
Balance, shares at Jul. 31, 2022		30,653,418
Balance at Oct. 31, 2022	28,200	$ 309	247,123	(218,385)	29,047	(847)
Balance, shares at Oct. 31, 2022		30,913,902
Stock option compensation to employees and directors	3,265		3,265		3,265
Common stock issued upon exercise of stock options and warrants	81	$ 1	80		81
Common stock issued upon exercise of stock options and warrants, shares		84,411
Common stock issued to consultants	67		67		67
Common stock issued to consultants, shares		17,554
Net loss	(7,209)			(7,121)	(7,121)	(88)
Balance at Jul. 31, 2023	24,585	$ 310	250,716	(225,506)	25,520	(935)
Balance, shares at Jul. 31, 2023		31,017,770
Stock options and warrants issued to consultants	175		175		175
Common stock issued pursuant to employee stock purchase plan	6		6		6
Common stock issued pursuant to employee stock purchase plan, shares		1,903
Balance at Apr. 30, 2023	25,913	$ 310	249,496	(222,995)	26,811	(898)
Balance, shares at Apr. 30, 2023		30,958,665
Stock option compensation to employees and directors	1,153		1,153		1,153
Stock options issued to consultants	47		47		47
Common stock issued upon exercise of stock options and warrants	3		3		3
Common stock issued upon exercise of stock options and warrants, shares		55,029
Common stock issued to consultants	17		17		17
Common stock issued to consultants, shares		4,076
Net loss	(2,548)			(2,511)	(2,511)	(37)
Balance at Jul. 31, 2023	$ 24,585	$ 310	$ 250,716	$ (225,506)	$ 25,520	$ (935)
Balance, shares at Jul. 31, 2023		31,017,770

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (7,209)	$ (10,242)
Stock option compensation to employees and directors	3,265	4,928
Stock options and warrants issued to consultants	175	546
Common stock issued to consultants	67	72
Amortization of operating lease right-of-use asset	34	31
Change in operating assets and liabilities:
Receivables	(288)
Prepaid expenses and other current assets	(65)	(400)
Accounts payable	(171)	91
Accrued expenses	(14)	103
Operating lease liability	(34)	(28)
Net cash used in operating activities	(4,240)	(4,899)
Cash flows from investing activities:
Disbursements to acquire short-term investments	(27,502)	(11,159)
Proceeds from maturities of short-term investments	22,493	10,348
Net cash used in investing activities	(5,009)	(811)
Cash flows from financing activities:
Proceeds from sale of common stock pursuant to employee stock purchase plan	6	6
Proceeds from exercise of stock options	81	830
Net cash provided by financing activities	87	836
Net decrease in cash and cash equivalents	(9,162)	(4,874)
Cash and cash equivalents at beginning of period	12,360	29,128
Cash and cash equivalents at end of period	$ 3,198	$ 24,254

BUSINESS AND FUNDING

BUSINESS AND FUNDING	9 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
BUSINESS AND FUNDING	1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our vaccine programs include (i) the development of a preventative vaccine against triple negative breast cancer (“TNBC”), the most lethal form of breast cancer, as well other forms of breast cancer and (ii) the development of a preventative vaccine against ovarian cancer. Our therapeutics programs include (i) the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), and (ii) until March 2023, the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. Utilizing this technology, we are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. The focus of this vaccine is a specific protein, α-lactalbumin, that is only expressed during lactation in a healthy mother’s mammary tissue. This protein disappears when the mother is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. Following the U.S. Food and Drug Administration’s (“FDA”) authorization to proceed with clinical trials in December 2020, in October 2021, we commenced dosing patients in a Phase 1 clinical trial of our breast cancer vaccine. This study, which is being funded by a U.S. Department of Defense grant, is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose (“MTD”) of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study is being conducted at Cleveland Clinic. The first segment of the study, Phase 1a, will consist of 18 to 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. Studies show that 42% of TNBC patients will have a recurrence of their cancer, with most of the recurrences occurring in the first two to three years after standard of care treatment. During the course of the Phase 1a study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. In April 2023, we presented the immunological data collected to date at the annual meeting of the American Association for Cancer Research. The data presented show that in the vaccinated women who had been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. In January 2023, the number of participants in each dose cohort was expanded, and as of August 2023, we have completed vaccinating all patients in these expanded cohorts. The patient blood samples are currently being analyzed, and we anticipate presenting data from all Phase 1a trial participants vaccinated to date at the San Antonio Breast Cancer Symposium in December 2023. In the coming months, we will begin vaccinating participants in two additional dose cohorts at dose levels higher than the currently determined maximum tolerated dose and lower than the highest dose where we saw dose limiting toxicity. Further, we have commenced recruitment for participants in the second segment of the trial, Phase 1b, that will include participants who have never had cancer, but carry certain genetic mutations that indicate a greater risk of developing TNBC in the future. Finally, we have also commenced recruitment for participants in the third segment of the trial, Phase 1c, that will include participants who are currently undergoing treatment with pembrolizumab (Keytruda®). In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to among other things, the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor 2 protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines during menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic to advance this vaccine toward human clinical testing. In May 2021, Cleveland Clinic was granted an award for our ovarian cancer vaccine technology by the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health (“NIH”). The PREVENT program is a peer-reviewed agent development program designed to support pre-clinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program are being used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and IND-enabling studies. This work is being performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the transfer of any rights of the Company’s assets. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading NCI designated cancer research center, relating to Wistar’s chimeric endocrine receptor targeted therapy technology. We have initially focused on the development of a treatment for ovarian cancer, but we also may pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), has begun human clinical testing of the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer. We received authorization from the FDA in August 2021, to commence enrollment and treatment of patients in a Phase 1 clinical trial. We began patient recruitment for the trial in March 2022, and in August 2022, we treated the first patient in the trial, and the treatment was well-tolerated by the patient. Further, in May 2023 and August 2023, we treated the second and third patients in the trial, respectively, at the same dose level as the first patient, and the treatment appears to have been well-tolerated by both patients. We anticipate that we will begin enrolling the successive patient cohort, that we expect to give a three-times higher dose of cells, in the fourth quarter of 2023. This study is a dose-escalation trial with two arms based on delivery method—intraperitoneal or intravenous—to determine the maximum tolerated dose in patients with recurrent epithelial ovarian cancer and to assess persistence, expansion and efficacy of the modified T-cells. The study is being conducted at Moffitt and will consist of 24 to 48 patients who have received at least two prior lines of chemotherapy. The study is estimated to be completed in two to four years depending on multiple factors including when maximum tolerated dose is reached, the rate of patient enrollment, and how long we maintain the two different delivery methods. In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”) which was later assigned to MolGenie GmbH (“MolGenie”), a company spun-out from OntoChem focused on drug discovery and development, to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we identified compounds that appeared to be effective in disrupting the main protease of SARS-CoV-2, the virus that causes the disease COVID-19. While our compounds have shown promise as an effective treatment, results of animal studies indicate that there is not sufficient oral bioavailability, and it is unclear whether an orally delivered treatment may be developed. We do not currently believe that there is a viable market for an injectable treatment given the current oral treatments available. Furthermore, we believe the needed additional investment in research for alternative delivery methods would divert resources from more promising projects. Therefore, on March 9, 2023, we decided to pause further development of our COVID-19 therapeutic. We continue to prosecute our U.S. patent applications of this technology and may decide to restart development at some time in the future. Over the next several quarters, we expect the development of our vaccines and therapeutics to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities of its various patent portfolios. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation (during the nine months ended July 31, 2023, we derived approximately $ 210,000 Funding and Management’s Plans Based on currently available information as of September 6, 2023, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. Under our at-the-market equity program as of July 31, 2023, we may sell up to $ 100

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. The accompanying October 31, 2022 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July 31, 2023, and results of operations and cash flows for the interim periods represented. The results of operations for the three and nine months ended July 31, 2023 are not necessarily indicative of the results to be expected for the year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2023 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2022 $ (847 ) Net loss attributable to noncontrolling interest (88 ) Balance, July 31, 2023 $ (935 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100 Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, developing anti-viral drug candidates for COVID-19 (through March 2023), developing our breast cancer vaccine, and developing our ovarian cancer vaccine, are expensed in the consolidated financial statements in the period incurred. Investment Policy The Company’s investment policy is to acquire debt securities with fixed maturities and contractual cash flows that the Company has the positive intent and ability to hold to maturity. These securities are recorded at amortized cost, net of any applicable discount which is amortized to interest income, and are accounted for as held-to-maturity securities.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Jul. 31, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	3. SHARE-BASED COMPENSATION The Company maintains equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. We recorded share-based compensation expense related to service-based stock options granted to employees and directors of approximately $ 1,153,000 941,000 3,265,000 2,546,000 For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On June 1, 2021, our Chairman and Chief Executive Officer and our President, Chief Operating Officer and Chief Financial Officer were awarded market condition stock options for 2,000,000 100,000 5.00 8.00 0 388,000 0 2,381,000 The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 47,000 109,000 175,000 326,000 For stock options granted to consultants that vest based on market conditions, such as changes in trading activity in the Company’s common stock, we use the Black-Scholes pricing model to estimate the fair value at the time which we believe the market conditions are reasonably likely to be met. On January 30, 2023, we granted market condition stock options to a consultant for 200,000 Stock Option Plans During the three months ended July 31, 2023, we had securities outstanding that were granted from two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Stock Option Activity During the three months ended July 31, 2023 and 2022, we did not grant any options to purchase shares of common stock, and during the nine months ended July 31, 2023 and 2022, we granted options to purchase 1,505,000 1,430,000 4.19 4.81 10,446 321,388 3,000 830,000 160,000 115,417 680,000 505,340 39,525 321,388 81,000 830,000 161,111 116,225 780,000 558,431 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the nine months ended July 31, 2023 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value (in thousands) Options outstanding at October 31, 2022 1,501,500 $ 2.83 Exercised (194,264 ) $ 2.46 Options outstanding and exercisable at July 31, 2023 1,307,236 $ 2.89 $ 1,252 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.67 2.27 462,500 3.1 $ 1.48 $ 2.58 3.13 335,736 2.3 $ 2.89 $ 3.46 5.30 509,000 4.8 $ 4.17 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of July 31, 2023, the 2018 Share Plan had 825,000 SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2022 8,817,372 $ 3.57 Granted 1,505,000 $ 4.29 Exercised (6,372 ) $ 2.89 Expirations (150,000 ) $ 5.30 Options outstanding at July 31, 2023 10,166,000 $ 3.68 $ 2,308 Options exercisable at July 31, 2023 6,366,137 $ 3.51 $ 1,699 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 2.09 3.87 5,341,000 6.7 $ 3.24 4,618,778 6.4 $ 3.31 $ 3.96 5.30 4,825,000 7.9 $ 4.16 1,747,359 7.1 $ 4.03 Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the “ESPP”) which permits eligible employees to purchase shares at not less than 85 1,903 2,389 6,000 6,000 Warrants On October 30, 2020, we issued a warrant, expiring on October 30, 2025 60,000 2.06 25,484 On November 1, 2021, we issued a warrant, expiring on October 30, 2026 60,000 4.77 five months 0 220,000 As of July 31, 2023, we also had warrants outstanding to purchase 300,000 6.56 March 22, 2026 Information regarding the Company’s warrants for the nine months ended July 31, 2023 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Aggregate Warrants outstanding at October 31, 2022 300,000 $ 6.56 Warrants outstanding and exercisable at July 31, 2023 300,000 $ 6.56 $ 0 The following table summarizes information about the Company’s outstanding and exercisable warrants as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 6.56 300,000 2.6 $ 6.56

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jul. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 – Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 – Financial instruments whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the instruments. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2023 (in thousands): SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 1,070 $ - $ - $ 1,070 Certificates of deposit: Cash equivalents - 1,981 - 1,981 Short-term investments - 6,850 - 6,850 U.S. treasury bills: Short-term investments - 15,486 - 15,486 Total financial assets $ 1,070 $ 24,317 $ - $ 25,387 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2022 (in thousands): Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 11,175 $ - $ - $ 11,175 Certificates of deposit: Cash equivalents - 1,000 - 1,000 Short term investments - 13,700 - 13,700 U.S. treasury bills - Short-term investments - 3,627 - 3,627 Total financial assets $ 11,175 $ 18,327 $ - $ 29,502 Our non-financial assets that are measured at fair value on a non-recurring basis are property and equipment and other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. The carrying value of cash equivalents approximates fair value.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Jul. 31, 2023
Payables and Accruals [Abstract]
ACCRUED EXPENSES	5. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, 2023 October 31, 2022 (in thousands) Payroll and related expenses $ 977 $ 492 Accrued royalty and contingent legal fees 626 577 Accrued collaborative research expenses 99 - Accrued other 10 26 Accrued expenses $ 1,712 $ 1,095

NET LOSS PER SHARE OF COMMON ST

NET LOSS PER SHARE OF COMMON STOCK	9 Months Ended
	Jul. 31, 2023
Net loss per common share attributable to common shareholders:
NET LOSS PER SHARE OF COMMON STOCK	6. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2023 and 2022, were stock options to purchase 11,473,236 11,094,104 300,000 300,000

EFFECT OF RECENTLY ADOPTED AND

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	9 Months Ended
	Jul. 31, 2023
Effect Of Recently Adopted And Issued Pronouncements
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	8. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382, the effects of which have not been determined by the Company. We have no

LEASES

LEASES	9 Months Ended
	Jul. 31, 2023
Leases
LEASES	9. LEASES We lease approximately 2,000 September 30, 2021 Effective August 17, 2021, the lease was amended to extend the expiration date to September 30, 2024, with an option to extend the lease an additional two years 5,000 3 260,000 10 17,000 17,000 50,000 50,000 For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments. The remaining 38 As of July 31, 2023, the annual minimum future lease payments of our operating lease liabilities were as follows (in thousands): SCHEDULE OF MINIMUM LEASE PAYMENTS For Periods Ended October 31, Operating Leases 2023 $ 17 2024 67 2025 70 2026 65 Total future minimum lease payments, undiscounted 219 Less: Imputed interest 32 Present value of future minimum lease payments $ 187

COMMITMENTS AND CONTINGENCES

COMMITMENTS AND CONTINGENCES	9 Months Ended
	Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCES	10. COMMITMENTS AND CONTINGENCES Litigation Matters Other than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Jul. 31, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2023 and 2022 and as of July 31, 2023 and October 31, 2022, in thousands: SCHEDULE OF SEGMENT INFORMATION 2023 2022 2023 2022 For the Three Months Ended July 31, For the Nine Months Ended July 31, 2023 2022 2023 2022 Net Loss: CAR-T Therapeutics $ (1,091 ) $ (965 ) $ (2,999 ) $ (3,975 ) Cancer Vaccines (1,390 ) (903 ) (3,261 ) (3,684 ) Anti-Viral Therapeutics (62 ) (904 ) (960 ) (2,565 ) Other (5 ) (3 ) 11 (18 ) Total $ (2,548 ) $ (2,775 ) $ (7,209 ) $ (10,242 ) Total operating costs and expenses $ 2,844 $ 2,797 $ 8,170 $ 10,266 Less non-cash share-based compensation (1,217 ) (1,446 ) (3,507 ) (5,546 ) Operating costs and expenses $ 1,627 $ 1,351 $ 4,663 $ 4,720 Operating costs and expenses excluding CAR-T Therapeutics $ 713 $ 421 $ 1,930 $ 1,823 Cancer Vaccines 855 376 1,966 1,571 Anti-Viral Therapeutics 55 552 572 1,312 Other 4 2 195 14 Total $ 1,627 $ 1,351 $ 4,663 $ 4,720 July 31, 2023 October 31, 2022 Total assets: CAR-T Therapeutics $ 11,640 $ 16,921 Cancer Vaccines 13,968 9,442 Anti-Viral Therapeutics 898 3,811 Other 72 238 Total $ 26,578 $ 30,412 Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise. The Company’s consolidated revenue of $ 210,000 161,000

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. The accompanying October 31, 2022 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July 31, 2023, and results of operations and cash flows for the interim periods represented. The results of operations for the three and nine months ended July 31, 2023 are not necessarily indicative of the results to be expected for the year.
Noncontrolling Interest	Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2023 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2022 $ (847 ) Net loss attributable to noncontrolling interest (88 ) Balance, July 31, 2023 $ (935 )
Revenue Recognition	Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100
Cost of Revenues	Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.
Research and Development Expenses	Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, developing anti-viral drug candidates for COVID-19 (through March 2023), developing our breast cancer vaccine, and developing our ovarian cancer vaccine, are expensed in the consolidated financial statements in the period incurred.
Investment Policy	Investment Policy The Company’s investment policy is to acquire debt securities with fixed maturities and contractual cash flows that the Company has the positive intent and ability to hold to maturity. These securities are recorded at amortized cost, net of any applicable discount which is amortized to interest income, and are accounted for as held-to-maturity securities.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST	Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2023 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2022 $ (847 ) Net loss attributable to noncontrolling interest (88 ) Balance, July 31, 2023 $ (935 )

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Jul. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF WARRANTS ACTIVITY	Information regarding the Company’s warrants for the nine months ended July 31, 2023 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Aggregate Warrants outstanding at October 31, 2022 300,000 $ 6.56 Warrants outstanding and exercisable at July 31, 2023 300,000 $ 6.56 $ 0
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about the Company’s outstanding and exercisable warrants as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 6.56 300,000 2.6 $ 6.56
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value (in thousands) Options outstanding at October 31, 2022 1,501,500 $ 2.83 Exercised (194,264 ) $ 2.46 Options outstanding and exercisable at July 31, 2023 1,307,236 $ 2.89 $ 1,252
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.67 2.27 462,500 3.1 $ 1.48 $ 2.58 3.13 335,736 2.3 $ 2.89 $ 3.46 5.30 509,000 4.8 $ 4.17
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2022 8,817,372 $ 3.57 Granted 1,505,000 $ 4.29 Exercised (6,372 ) $ 2.89 Expirations (150,000 ) $ 5.30 Options outstanding at July 31, 2023 10,166,000 $ 3.68 $ 2,308 Options exercisable at July 31, 2023 6,366,137 $ 3.51 $ 1,699
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 2.09 3.87 5,341,000 6.7 $ 3.24 4,618,778 6.4 $ 3.31 $ 3.96 5.30 4,825,000 7.9 $ 4.16 1,747,359 7.1 $ 4.03

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jul. 31, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS	The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2023 (in thousands): SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 1,070 $ - $ - $ 1,070 Certificates of deposit: Cash equivalents - 1,981 - 1,981 Short-term investments - 6,850 - 6,850 U.S. treasury bills: Short-term investments - 15,486 - 15,486 Total financial assets $ 1,070 $ 24,317 $ - $ 25,387 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2022 (in thousands): Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 11,175 $ - $ - $ 11,175 Certificates of deposit: Cash equivalents - 1,000 - 1,000 Short term investments - 13,700 - 13,700 U.S. treasury bills - Short-term investments - 3,627 - 3,627 Total financial assets $ 11,175 $ 18,327 $ - $ 29,502

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Jul. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, 2023 October 31, 2022 (in thousands) Payroll and related expenses $ 977 $ 492 Accrued royalty and contingent legal fees 626 577 Accrued collaborative research expenses 99 - Accrued other 10 26 Accrued expenses $ 1,712 $ 1,095

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Jul. 31, 2023
Leases
SCHEDULE OF MINIMUM LEASE PAYMENTS	As of July 31, 2023, the annual minimum future lease payments of our operating lease liabilities were as follows (in thousands): SCHEDULE OF MINIMUM LEASE PAYMENTS For Periods Ended October 31, Operating Leases 2023 $ 17 2024 67 2025 70 2026 65 Total future minimum lease payments, undiscounted 219 Less: Imputed interest 32 Present value of future minimum lease payments $ 187

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Jul. 31, 2023
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT INFORMATION	SCHEDULE OF SEGMENT INFORMATION 2023 2022 2023 2022 For the Three Months Ended July 31, For the Nine Months Ended July 31, 2023 2022 2023 2022 Net Loss: CAR-T Therapeutics $ (1,091 ) $ (965 ) $ (2,999 ) $ (3,975 ) Cancer Vaccines (1,390 ) (903 ) (3,261 ) (3,684 ) Anti-Viral Therapeutics (62 ) (904 ) (960 ) (2,565 ) Other (5 ) (3 ) 11 (18 ) Total $ (2,548 ) $ (2,775 ) $ (7,209 ) $ (10,242 ) Total operating costs and expenses $ 2,844 $ 2,797 $ 8,170 $ 10,266 Less non-cash share-based compensation (1,217 ) (1,446 ) (3,507 ) (5,546 ) Operating costs and expenses $ 1,627 $ 1,351 $ 4,663 $ 4,720 Operating costs and expenses excluding CAR-T Therapeutics $ 713 $ 421 $ 1,930 $ 1,823 Cancer Vaccines 855 376 1,966 1,571 Anti-Viral Therapeutics 55 552 572 1,312 Other 4 2 195 14 Total $ 1,627 $ 1,351 $ 4,663 $ 4,720 July 31, 2023 October 31, 2022 Total assets: CAR-T Therapeutics $ 11,640 $ 16,921 Cancer Vaccines 13,968 9,442 Anti-Viral Therapeutics 898 3,811 Other 72 238 Total $ 26,578 $ 30,412

SCHEDULE OF CHANGES IN NONCONTR

SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Accounting Policies [Abstract]
Beginning balance			$ (847)
Net loss attributable to noncontrolling interest	$ (37)	$ (29)	(88)	$ (123)
Ending balance	$ (935)		$ (935)

BUSINESS AND FUNDING (Details N

BUSINESS AND FUNDING (Details Narrative)	9 Months Ended
	Jul. 31, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Litigation settlement expense	$ 210,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Proceeds from sale of common stock	$ 100,000,000
The Wistar Institute [Member]
Property, Plant and Equipment [Line Items]
Ownership percentage	5%

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	9 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Revenue percentage	100%

SCHEDULE OF OPTION ACTIVITY (De

SCHEDULE OF OPTION ACTIVITY (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Jul. 31, 2023 USD ($) $ / shares shares
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, options outstanding, beginning balance | shares	1,501,500
Weighted Average Exercise Price Per Share, Outstanding Beginning balance | $ / shares	$ 2.83
Shares, options, exercised | shares	(194,264)
Weighted average exercise price per share, exercised | $ / shares	$ 2.46
Shares, Options outstanding, Ending balance | shares	1,307,236
Weighted Average Exercise Price Per Share, Outstanding Ending balance | $ / shares	$ 2.89
Aggregate intrinsic value, outstanding and exercisable | $	$ 1,252
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, options outstanding, beginning balance | shares	8,817,372
Weighted Average Exercise Price Per Share, Outstanding Beginning balance | $ / shares	$ 3.57
Shares, options, exercised | shares	(6,372)
Weighted average exercise price per share, exercised | $ / shares	$ 2.89
Shares, Options outstanding, Ending balance | shares	10,166,000
Weighted Average Exercise Price Per Share, Outstanding Ending balance | $ / shares	$ 3.68
Shares, options, granted | shares	1,505,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 4.29
Shares, options, exercised | shares	(150,000)
Weighted average exercise price per share, exercised | $ / shares	$ 5.30
Aggregate Intrinsic Value, Outstanding Ending balance | $	$ 2,308
Shares, Options outstanding, Exercisable | shares	6,366,137
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 3.51
Aggregate Intrinsic Value, Exercisable | $	$ 1,699

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE (Details) - $ / shares	9 Months Ended
	Jul. 31, 2023	Oct. 31, 2022
Range One [Member] | Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	300,000
Weighted average remaining contractual life	2 years 7 months 6 days
Weighted average exercise price	$ 6.56
Range of exercise prices	$ 6.56
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	1,307,236	1,501,500
Weighted average exercise price	$ 2.89	$ 2.83
2010 Share Plan [Member] | Range One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise prices, lower limit	0.67
Range of exercise prices, upper limit	$ 2.27
Number outstanding and exercisable	462,500
Weighted average remaining contractual life	3 years 1 month 6 days
Weighted average exercise price	$ 1.48
2010 Share Plan [Member] | Range Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise prices, lower limit	2.58
Range of exercise prices, upper limit	$ 3.13
Number outstanding and exercisable	335,736
Weighted average remaining contractual life	2 years 3 months 18 days
Weighted average exercise price	$ 2.89
2010 Share Plan [Member] | Range Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise prices, lower limit	3.46
Range of exercise prices, upper limit	$ 5.30
Number outstanding and exercisable	509,000
Weighted average remaining contractual life	4 years 9 months 18 days
Weighted average exercise price	$ 4.17
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	10,166,000	8,817,372
Weighted average exercise price	$ 3.68	$ 3.57
Number exercisable, options exercisable	6,366,137
Weighted average exercise price, options exercisable	$ 3.51
2018 Share Plan [Member] | Range One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise prices, lower limit	2.09
Range of exercise prices, upper limit	$ 3.87
Number outstanding and exercisable	5,341,000
Weighted average remaining contractual life	6 years 8 months 12 days
Weighted average exercise price	$ 3.24
Number exercisable, options exercisable	4,618,778
Weighted average remaining contractual life (in years), options exercisable	6 years 4 months 24 days
Weighted average exercise price, options exercisable	$ 3.31
2018 Share Plan [Member] | Range Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise prices, lower limit	3.96
Range of exercise prices, upper limit	$ 5.30
Number outstanding and exercisable	4,825,000
Weighted average remaining contractual life	7 years 10 months 24 days
Weighted average exercise price	$ 4.16
Number exercisable, options exercisable	1,747,359
Weighted average remaining contractual life (in years), options exercisable	7 years 1 month 6 days
Weighted average exercise price, options exercisable	$ 4.03

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) $ / shares in Units, $ in Thousands	Jul. 31, 2023 USD ($) $ / shares shares
Weighted average exercise price per share warrants outstanding, beginning balance | $ / shares	$ 6.56
Weighted average exercise price per share warrants outstanding and exercisable, ending balance | $ / shares	$ 6.56
Aggregate intrinsic value, Warrants outstanding and exercisable, ending balance | $	$ 0
Warrant [Member]
Warrants outstanding, beginning balance | shares	300,000
Warrants outstanding and exercisable, ending balance | shares	300,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)						3 Months Ended		9 Months Ended
	Jan. 30, 2023	Nov. 16, 2021	Nov. 01, 2021	Jun. 01, 2021	Oct. 30, 2020	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option exercised						$ 3,000	$ 830,000	$ 81,000	$ 830,000
Common stock issued pursuant to employee stock purchase plan, value								6,000	6,000
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option exercised							$ 5,000	$ 1,000	$ 6,000
Option to purchase common stock						55,029	496,048	84,411	577,473
Common stock issued pursuant to employee stock purchase plan, shares								1,903	2,389
Common stock issued pursuant to employee stock purchase plan, value
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrant expiration date			Oct. 30, 2026		Oct. 30, 2025
Warrant exercise price						$ 6.56		$ 6.56
Vesting period			5 months
Consulting expense							$ 0		$ 220,000
Warrants to purchase common stock						300,000		300,000
Warrants maturity date						Mar. 22, 2026		Mar. 22, 2026
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted								1,505,000
Exercise price								$ 2.89
Option to purchase common stock								6,372
Shares available for future grants						825,000		825,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase price of common stock percentage								85%
Common stock issued pursuant to employee stock purchase plan, shares								1,903	2,389
Common stock issued pursuant to employee stock purchase plan, value								$ 6,000	$ 6,000
Equity Option [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted				2,000,000
Equity Option [Member] | 2018 Share Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 5
Equity Option [Member] | 2018 Share Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 8
Equity Option [Member] | 2018 Share Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted				100,000
Non Vested Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation						$ 0	$ 388,000	$ 0	$ 2,381,000
Stock Option Activity [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted	200,000
Option to purchase common stock						10,446	321,388	39,525	321,388
Stock option exercised						$ 3,000	$ 830,000	$ 81,000	$ 830,000
Option to purchase common stock						160,000	680,000	161,111	780,000
Option to purchase common stock withheld						115,417	505,340	116,225	558,431
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation						$ 1,153,000	$ 941,000	$ 3,265,000	$ 2,546,000
Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted						$ 47,000	$ 109,000	$ 175,000	$ 326,000
Consultants [Member] | Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants purchase of common stock			60,000		60,000
Warrant exercise price			$ 4.77		$ 2.06
Number of shares as payment		25,484
Employees and Consultants [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted								1,505,000	1,430,000
Employees and Consultants [Member] | 2018 Share Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share exercise price						$ 4.19		$ 4.19
Employees and Consultants [Member] | 2018 Share Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share exercise price						$ 4.81		$ 4.81

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Oct. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	$ 25,387	$ 29,502
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,070	11,175
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,981	1,000
Short-term investments	6,850	13,700
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	15,486	3,627
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	1,070	11,175
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,070	11,175
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Short-term investments
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	24,317	18,327
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,981	1,000
Short-term investments	6,850	13,700
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	15,486	3,627
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Short-term investments
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Oct. 31, 2022
Payables and Accruals [Abstract]
Payroll and related expenses	$ 977	$ 492
Accrued royalty and contingent legal fees	626	577
Accrued collaborative research expenses	99
Accrued other	10	26
Accrued expenses	$ 1,712	$ 1,095

NET LOSS PER SHARE OF COMMON _2

NET LOSS PER SHARE OF COMMON STOCK (Details Narrative) - shares	9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	11,473,236	11,094,104
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	300,000	300,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Jul. 31, 2023	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits, penalties	$ 0	$ 0

SCHEDULE OF MINIMUM LEASE PAYME

SCHEDULE OF MINIMUM LEASE PAYMENTS (Details) $ in Thousands	Jul. 31, 2023 USD ($)
Leases
2023	$ 17
2024	67
2025	70
2026	65
Total future minimum lease payments, undiscounted	219
Less: Imputed interest	32
Present value of future minimum lease payments	$ 187

LEASES (Details Narrative)

LEASES (Details Narrative)	3 Months Ended		9 Months Ended
	Jul. 31, 2023 USD ($) ft²	Jul. 31, 2022 USD ($)	Jul. 31, 2023 USD ($) ft²	Jul. 31, 2022 USD ($)
Payments for rent	$ 17,000	$ 17,000	$ 50,000	$ 50,000
Almaden Expressway San Jose [Member]
Area of land | ft²	2,000		2,000
Lease expiration date			Sep. 30, 2021
Lease extension			Effective August 17, 2021, the lease was amended to extend the expiration date to September 30, 2024, with an option to extend the lease an additional two years
Payments for rent			$ 5,000
Rent percentage			3%
Right of use asset obtained in exchange for operating lease liability			$ 260,000
Operating lease weighted average discount rate percent	10%		10%
Lessee operating lease term of contract	38 months		38 months

SCHEDULE OF SEGMENT INFORMATION

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022	Oct. 31, 2022
Segment Reporting Information [Line Items]
Total	$ (2,548)	$ (2,775)	$ (7,209)	$ (10,242)
Total operating costs and expenses	2,844	2,797	8,170	10,266
Less non-cash share-based compensation	(1,217)	(1,446)	(3,507)	(5,546)
Total	1,627	1,351	4,663	4,720
Total	26,578		26,578		$ 30,412
Cart Therapeutics [Member]
Segment Reporting Information [Line Items]
Total	(1,091)	(965)	(2,999)	(3,975)
Total	713	421	1,930	1,823
Total	11,640		11,640		16,921
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Total	(1,390)	(903)	(3,261)	(3,684)
Total	855	376	1,966	1,571
Total	13,968		13,968		9,442
Anti Viral Therapeutics [Member]
Segment Reporting Information [Line Items]
Total	(62)	(904)	(960)	(2,565)
Total	55	552	572	1,312
Total	898		898		3,811
Other [Member]
Segment Reporting Information [Line Items]
Total	(5)	(3)	11	(18)
Total	4	$ 2	195	$ 14
Total	$ 72		$ 72		$ 238

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Jul. 31, 2023 USD ($)
Segment Reporting [Abstract]
Revenue	$ 210,000
Royalties, legal fees, litigation and licensing expense	$ 161,000